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Background: The clinical application of nimodipine (NIM) is limited by several unfavorable 
properties, which are induced by its low aqueous solubility. In the present study, nimodipine-
loaded egg phosphatidylcholine-sodium glycocholate mixed micelles (NIM-EPC-SGC-MMs) 
were prepared to improve the water solubility of NIM, thus allowing it to be more applicable 
for clinical use.
Methods: NIM-EPC-SGC-MMs were prepared using the coprecipitation method and the 
factors influencing formulation quality were optimized. After formulation, water solubility, 
solubilizing efficiency, drug loading, particle size, physical compatibility, pharmacokinetics, 
and vascular irritability were determined.
Results: The mean size of the NIM-EPC-SGC-MMs was 6.099 ± 0.048 nm under optimized 
conditions. The water solubility of NIM in EPC-SGC-MMs was enhanced 250-fold compared 
with free NIM. The physical compatibility, pharmacokinetic, and vascular irritability studies 
showed that, in comparison to the commercially available NIM injections, NIM-EPC-SGC-
MMs presented better physical compatibility, the same pharmacokinetic profile, and less risk 
of local vascular irritation and phlebitis.
Conclusion: EPC-SGC-MMs represent a promising new formulation suitable for the intrave-
nous delivery of NIM.
Keywords: drug loading, nimodipine injection, physical compatibility, solubilizing 
efficiency
Introduction
Nimodipine (NIM) is a 1,4-dihydropyridine calcium channel blocker (Figure 1), which 
has been shown to dilate cerebral arterioles and increase cerebral blood flow.1 It has 
been reported to possess beneficial pharmacological activity in the treatment of a range 
of cerebrovascular disorders.1,2 The therapeutic use of NIM includes that in subarach-
noid hemorrhage, focal or global ischemia, and epilepsy.2,3 Presently, NIM is also used 
for acute ischemic stroke, migraines, cerebral vasospasm, multi-infarct dementia, and 
hypotension-induced memory impairment.4–9 Despite the promising biological effects 
of NIM, its clinical performance is restricted by its low oral bioavailability (as low as 
10%) and low aqueous solubility (3.86 µg/mL).9,10 Thus, intravenous administration is 
the alternative route for NIM in case of efficacy. To achieve a sufficient NIM concen-
tration, a commercial injection of NIM has been produced by solubilizing NIM with 
about 40% solvent mixture: 23.7% (v/v) ethanol and 17% (v/v) polyethylene glycol 
400.11 However, this concentration has many noticeable drawbacks when applied in 
the clinic. For instance, according to the intravenous dosage regimen, this formulation 
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requires a time-consuming administration (about 10 hours by 
infusion pump), as well as special equipment and additional 
nursing care.11,12 Further, NIM-ethanol injections may cause 
local adverse reactions at the administration site, such as pain 
and inflammation.9,11 Of more concern, there may be phlebitis 
during infusion and poor patient compliance. In addition, 
crystallization caused by the poor water solubility of NIM 
can also occur when the NIM injection is diluted by injection 
solutions, which is dangerous to patients.13   Consequently, 
the application of these NIM commercial injections has been 
limited by their high medication cost, low patient compliance, 
and safety considerations.
Thus, there is a pressing need to develop a safe, injectable 
formulation for NIM by means of pharmaceutics. Based on 
its physiological compatibility and solubilizing capacity, 
a phosphatidylcholine (PC)-bile salts (BS)-mixed micelle 
(MM) formulation is an attractive candidate for the intrave-
nous administration of poorly soluble drugs.14–20 This simple 
approach of combining a water-soluble surfactant with a 
water-insoluble phospholipid results in an isotropically clear 
solution.21,22 Many studies have been published regarding 
the preparation and characterization of PC-BS-MMs.16,23–26 
BS present in bile with a high concentration can solubilize 
PC to a large extent, forming a kind of clear mixed-micellar 
solution that in turn can solubilize substances with poor 
water solubility.16,19 With the solubilized phospholipids, the 
hemolytic effects of BS can be neutralized.27 Most impor-
tantly, PC-BS-MMs have been proven to be locally and 
systemically well tolerated, with no embryotoxic, terato-
genic, or mutagenic effects after administration.28 Without 
a toxicologically solvent mixture, a PC-BS-MM formulation 
can reduce irritation and improve the patient compliance. 
Consequently, PC-BS-MMs are an ideal drug carrier for the 
intravenous administration of NIM.
In this study, our objective was to develop a novel 
  potential delivery vehicle for NIM that could be used in the 
clinic. First, we prepared and characterized NIM-loaded 
egg phosphatidylcholine (EPC)-sodium glycocholate 
  (SGC)-mixed micelles (MMs). We then compared and 
studied the pharmacokinetic properties of NIM-EPC-SGC-
MMs versus NIM injection. We also compared the physical 
compatibility of the infusion solutions and the intravenous 
irritation of NIM-EPC-SGC-MMs compared with NIM 
injection.
Materials and methods
Reagents and chemicals
NIM  was  kindly  supplied  by  Chongqing Yaoyou 
  Pharmaceutical Co, Ltd (Chongqing, China). EPC   (purified 
ovolecithin), purity 80%, was obtained from Lipoid GmbH 
(Ludwigshafen, Germany). Pyrene was purchased from 
Sigma Aldrich (Munich, Germany) and used without further 
purification. SGC was a gift from Chongqing Yaoyou Pharma-
ceutical Co, Ltd. The commercially available NIM injection 
(0.2 mg/mL, batch number: 110101) was purchased from Ya 
Bao Pharmaceutical Group Co, Ltd (Shanxi, China). Refer-
ence substances of nitrendipine (number: 100585-200602) 
and NIM (number: 100270-200002) were purchased from 
Chengdu Rong Jin Medical Technology   Development Co, 
Ltd (Chengdu, China). Sodium chloride injection (batch 
number: 1191022) was purchased from Taiji Group South-
west Pharmaceutical Co, Ltd   (Chongqing, China). Double-
distilled (DI) water and the other chemical reagents were of 
analytical grade or better.
Animals
Male Wistar rats (weight 200 ± 20 g) and Japanese big-ear 
rabbits (weight 2.5–3.0 kg) were provided by the Laboratory 
Animal Center of Sichuan University (Chengdu, China). The 
protocols and procedures were recognized by the Institutional 
Animal Care and Use Committee of Sichuan University.
Preparation of NIM-EPC-SGC-MMs
Due to the good solubility of NIM, SGC, and EPC in anhy-
drous ethanol, NIM was easily loaded into PC-BS-MMs 
using the coprecipitation method.26 Briefly, NIM, SGC, and 
EPC (at different molar ratios and concentrations) were 
  dissolved by anhydrous ethanol in a 25 mL round-bottom 
flask. The organic solvent was evaporated at 60°C under 
vacuum to form a thin film that was then rehydrated in 
physiological saline and dispersed by slight shaking before 
the pH was adjusted to about 7.4. To remove the unloaded 
drug, the solution was centrifuged at 10,000 × g in an Allegra 
X-22R Centrifuge with a F2402H rotor (Beckman Coulter 
Inc, Brea, CA) for 5 minutes and the supernatant containing 
freshly formed MMs was collected.
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Figure 1 Chemical structure of nimodipine.
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Based on the single-factor method, a high-quality formu-
lation was obtained by optimizing several main formulation 
factors, including the ratio of the mass concentration of 
EPC and SGC, the total concentration of EPC and SGC, the 
dose of NIM, and the pH value of dispersed medium. Each 
experiment was run in triplicate.
Critical micelle concentration (CMC) 
determination
The CMC of the binary mixture of EPC-SGC (the optimal ratio) 
in DI water was determined by the pyrene 1:3 ratio method.29 
Samples of MMs of different concentrations ranging from 4% 
to 1 × 10–4% were prepared. Pyrene, dissolved in methanol, 
was added to EPC-SGC-MMs with different concentrations 
to obtain a final concentration of 4 × 10–7 mol/L. The mixtures 
were balanced for 24 hours in a dark room at room temperature 
before measurement and plated in 96-well plates for fluores-
cence measurements (using a Fluoroskan Ascent FL; Thermo 
Scientific, Waltham, MA). Fluorescence emission spectra 
of pyrene were obtained using an excitation wavelength of 
336 nm, with an emission slit of 5 nm. The intensities, I1 and 
I3, were measured at the wavelengths corresponding to the first 
and third vibronic bands located near 372 and 383 nm. All fluo-
rescence measurements were carried out at 25°C. Experiments 
were performed in triplicate. The ratio of I1 to I3 for pyrene 
was 1:3.29 The pyrene 1:3 ratio data were analyzed with Origin 
8.5 software (OriginLab Corp, Northampton, MA).
Measurement of particle size
The particle size and polydispersity index of the formed   optimal 
MMs were measured by dynamic light scattering (Malvern 
Zetasizer Nano ZS90, Malvern Instruments Ltd, Malvern, UK) 
at 25°C. The samples were measured with no dilution.
Transmission electron microscopy
The morphology of optimum NIM-EPC-SGC-MMs was 
observed with a field-emission high-resolution transmission 
electron microscope (TEM) (Tecnai G2 F20, FEI, Eindhoven, 
The Netherlands). The sample was placed on copper grids and 
stained with 2% (w/v) phosphotungstic acid for 30 seconds. 
After the excess solution was drawn off and the sample was 
allowed to dry, it was subjected to TEM observation.
Drug solubility, solubilizing efficiency,  
and drug loading of NIM-EPC-SGC-MMs
The concentration of the NIM solubilized by   optimal EPC-
SGC-MMs was determined by reverse-phase   high-performance 
  liquid chromatography (HPLC) on three parallel   measurements. 
After dilution with methanol, the NIM-EPC-SGC-MMs were 
injected into an HPLC system. The analysis was performed 
on an Agilent 1260 infinity LC system (with a G1329B 
autosampler, G1312B pump, and G1314B detector; Agilent 
  Technologies, Inc, Santa Clara, CA), equipped with a Kromasil 
C18 column (250 × 4.6 mm, 5 µm; Bohus, Sweden) kept at 
40°C as the stationary phase. The analysis parameters for NIM 
were as follows: the mobile phase consisted of a mixture of 
methanol, acetonitrile, and DI water (35:38:27); the injection 
volume of the samples and standards was 20 µL; the flow 
rate was set at 1.0 mL/min, and the detection wavelength was 
237 nm by ultraviolet detection.
Solubilizing efficiency and drug loading (DL%) were 
calculated by the following equations:
Solubilizing efficiency (%)  
  =   (Weight of NIM in micelles 
/Weight of NIM feeding) × 100%  (1)
DL% =   (Weight of NIM in micelles/Weight of feeding 
EPC and SGC and NIM) × 100%  (2)
Physical compatibility study with sodium 
chloride injection, glucose injection,  
and sterile water
The NIM-EPC-SGC-MMs and NIM injection were diluted 
by certain degrees – 10-fold, 100-fold, 500-fold – by sodium 
chloride injection, glucose injection, and sterile water, 
  respectively. Each sample was placed in a 10 mL tube and 
examined for observable small particles and low-level 
haze30 in normal fluorescent light from a Tyndall beam 
(high-  intensity mono-directional light source) using the 
unaided eye. As a standard, the turbidity of each sample 
was measured. All of the samples were kept at room tem-
perature and observed at fixed time points (0, 0.5,1, 5 and 
10 hours).
In vivo studies in rats
Ten male Wistar rats (200 ± 20 g) were randomly divided 
into two groups, with five rats in each group. Rats were 
fasted overnight but supplied with water before the 
  experiment. The NIM injection and NIM-EPC-SGC-
MMs, with the same mass concentration of NIM, were 
  administered by intravenous injection through the tail vein 
at a dose of 2 mg/kg.
After administration, blood was collected from the ocular 
vein at predetermined time points (5, 15, 30, 45, 60, 120, 240, 
300 minutes). Plasma samples (0.5 mL) were placed into 
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heparinized centrifuge tubes; plasma samples (100 µL) were 
collected immediately following centrifugation at 1296 × g 
for 10 min and then stored at −20°C until further use.
Determination of NIM in plasma  
samples by hPLC
The concentration of NIM in blood was determined by a 
reverse-phase HPLC method.31 In brief, 100 µL of plasma 
was mixed with 25 µL of internal standard (nitrendipine at 
a concentration of 0.0020 mg/mL in methanol), followed by 
vortex mixing for 1 minute. Then, 50 µL of 1 mol/L NaOH 
was added and the mixture was extracted with 0.4 mL 
N-hexane-ethyl ether (1:1) twice. After vortex for 1 minute 
and centrifugation at 12,000 × g for 10 minutes, the super-
natant was collected and combined, followed by evapora-
tion under nitrogen at 50°C. The residue was dissolved into 
100 µL mobile phase after vortexing for 30 seconds and 
centrifuged at 12,000 × g for 10 minutes sequentially; 50 µL 
of the resultant supernatant was subjected to HPLC analysis. 
A reverse-phase column (C18, 250 × 4.6 mm, 5 µm) was 
used with a security guard column (C18, 10 × 4 mm, 5 µm), 
  (Phenomenex, Torrance, CA). Under a column temperature of 
35°C, the mobile phase consisted of a mixture of acetonitrile 
− 0.05 mol/L ammonium acetate (60:40). The flow rate was 
1.0 mL/min and the detection wavelength was 358 nm.
Vascular irritability study in rabbits
Six male rabbits (weight 2.5–3.0 kg) were randomly divided 
into two groups. One group was injected with NIM-EPC-
SGC-MMs and sodium chloride injection. The other group 
was injected with the commercial NIM injection and sodium 
chloride injection as a control. Each group was injected 
according to a clinical dosing regimen of 0.4 mg/kg for 
5 days. In brief, animals in the first group were administered 
an NIM injection of clinical concentration via ear vein infu-
sion on the right and received a sodium chloride injection 
on the left. The second group was injected with NIM-EPC-
SGC-MMs of clinical concentration via vein infusion on 
the right ear and received a sodium chloride injection on the 
left. Visual observations of the injection site and surround-
ing tissue were made and recorded as pathological samples 
at intervals until 48 hours; at that time, each group was 
sacrificed. After being fixed in 10% v/v formaldehyde in 
physiological saline for 48 hours, the obtained samples were 
serially dehydrated by different concentrations of ethanol 
(100%, 95%, 85%, 70%, 2–5 minutes for each concentration). 
The dehydrated samples were embedded in paraffin and cut 
and stained using   hematoxylin and eosin. All sections were 
observed at × 100 magnification with an Axiovert200 (Zeiss, 
Oberkochen, Germany), and pathological changes were ana-
lyzed and evaluated.
Statistical analysis
The measured plasma concentration data were analyzed 
using non-linear regression analysis with the use of Drug and 
Statistics Software (DAS 2.0; Mathematical   Pharmacology 
Professional Committee of China, Shanghai, China); the best 
compartment model for estimating pharmacokinetic   parameters 
was then determined. After we analyzed the   Student’s t-test 
results of the two groups, we determined that a P value , 0.05 
would be considered statistically significant.
Results
Determination of solubilizing efficiency 
of NIM-EPC-SGC-MMs in different 
formulations
The influence of the EPC/SGC mass concentration ratio on 
the solubilizing efficiency of the NIM-EPC-SGC-MMs (NIM 
concentration was kept at 0.5 mg/mL) is shown in Figure 2. 
When the EPC/SGC mass concentration ratio decreased 
from 1:0.7 to 1:1, a significant increase in NIM solubilizing 
efficiency was observed. However, a further decrease in the 
EPC/SGC mass concentration ratio (from 1:1 to 0:1) did not 
improve NIM solubilizing efficiency – remarkably, it reduced 
the solubilizing efficiency. The EPC/SGC concentration ratio 
of 1:1 was used for the subsequent studies, as the solubilizing 
efficiency under such conditions could be up to 96.40%.
When the mass concentration of NIM in water was set 
at 0.5 mg/mL, the influence of the total concentration of 
SGC and EPC on NIM solubilizing efficiency was also 
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Figure 2 Influence of the mass concentration ratio of EPC and SGC on NIM 
solubilizing efficiency at 25°C (n = 3).
Abbreviations: EPC, egg phosphatidylcholine; SGC, sodium glycocholate; NIM, 
nimodipine.
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  investigated. As shown in Figure 3, NIM solubilizing 
  efficiency was improved by increasing the total concentration 
of SGC and EPC in the MM system. The solubilizing effi-
ciency did not further improve when the total concentration 
of SGC and EPC was higher than 40 mg/mL.
The effect of NIM concentration on the stability of the 
NIM-EPC-SGC-MMs is shown in Table 1. The results 
showed that NIM concentration could affect the stability of 
the NIM-EPC-SGC-MMs. The limiting concentration of NIM 
in this optimized EPC-SGC-MM system was 0.5 mg/mL, 
since further increases in the concentration of NIM resulted 
in the instability of the NIM-EPC-SGC-MMs, as indicated 
by the separation of NIM from the formulation.
The influence of pH value on the solubilizing efficiency 
of NIM in EPC-SGC-MMs is shown in Figure 4. An 
increase in pH value of the EPC-SGC-MM solvent could 
dramatically enhance the solubilizing efficiency of NIM 
when the pH value was between 2 and 6. With pH values 
higher than 6, the solubilizing efficiency of NIM showed 
a slight   fluctuation. Nevertheless, phospholipids in neutral 
pH (6.5) have the greatest stability.32 A pH of 7.4 is relevant 
to physiology. When pH values were about 7.4, the solubiliz-
ing efficiency could be up to 96.40%. Hence, pH was settled 
at approximately 7.4.
The effect of ionic strength on the solubilizing efficiency 
of NIM-EPC-SGC-MMs was not studied because physiologi-
cal saline was the only dispersion solution.
CMC determination
With Origin 8.5 software, pyrene 1:3 ratio plots could be 
adequately described by the Boltzmann-type approach29,33 
(Figure 5), which is shown by the following equation:
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Figure 3 Influence of the total concentration of SGC and EPC on NIM solubilizing 
efficiency at 25°C (n = 3).
Abbreviations: EPC, egg phosphatidylcholine; SGC, sodium glycocholate; NIM, 
nimodipine.
Table 1 Influence of NIM concentration on the stability of NIM-
EPC-SGC-MMs
NIM (mg/mL) EPC + SGC (mg) Time (h)
0 1 24 48 72
0.5 40 Y Y Y Y Y
0.8 40 Y Y Y Y C
1 40 Y Y Y C C
1.6 40 C C C C C
2 40 C C C C C
Notes: Y = settled solution; C = NIM separating out; n = 3. 
Abbreviations:  NIM,  nimodipine;  EPC,  egg  phosphatidylcholine;  SGC,  sodium 
glycocholate;  NIM-EPC-SGC-MMs,  nimodipine-egg  phosphatidylcholine-sodium 
glycocholate-mixed micelles.
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
024681 01 2
pH value of dispersed medium
S
o
l
u
b
i
l
i
z
i
n
g
 
e
f
f
i
c
i
e
n
c
y
Figure 4 Influence of pH value of dispersed medium on NIM solubilizing efficiency 
at 25°C (n = 3).
Abbreviation: NIM, nimodipine.
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Figure 5 Plot of the fluorescence of pyrene I1/I3 intensity ratio versus concentration 
of EPC/SGC mixed micelles (mass ratio 1:1) in distilled water at 25°C (n = 3).
Abbreviations:  EPC,  egg  phosphatidylcholine;  SGC,  sodium  glycocholate;  I1/I3, 
intensity of the third to the first peak (372 and 383 nm) of pyrene.
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where the variable y is the pyrene 1:3 ratio value, the independent 
variable (χ) is the total concentration of surfactant, and A1 and 
A2 correspond to the upper and lower limits of sigmoid, respec-
tively; χ0 is the center of the sigmoid and ∆χ is directly related 
to the independent variable occurence. As shown in Figure 5, 
the shape of the plots exhibited a typically sigmoidal decrease. 
For the Boltzmann-type equation, the values for A1, A2, χ0, and 
∆χ were 1.55, 0.85, −3.02, and 0.36, respectively. R2 was 0.99, 
indicating that the Boltzmann-type model was consistent with 
the typically sigmoidal decrease of the plot. As the value of χ0/∆χ 
was less than 10, χ0 should be the CMC value.29 Consequently, 
the CMC value of EPC/SGC (1:1) was 0.0095 mg/mL.
Drug solubility, solubilizing efficiency,  
and drug loading of NIM-EPC-SGC-MMs
The optimized formulation, composed of 1.25 mg NIM, 
50 mg SGC, 50 mg E80, and 2.5 mL physiological saline, 
was further characterized by three separate and parallel 
measurements. As shown in Table 2, the NIM water solu-
bility, solubilizing efficiency, and drug loading of the opti-
mized NIM-EPC-SGC-MMs were 0.468 ± 0.009 mg/mL, 
93.8% ± 2.2%, and 1.17% ± 0.02%, respectively.
Particle size and morphology
The mean size of the optimal NIM-EPC-SGC-MMs, based on 
three separate measurements, was 6.099 ± 0.048 nm, with a poly-
dispersity index of 0.107 ± 0.016 (Figure 6A). In addition, the 
TEM study showed that the NIM-EPC-SGC-MMs were spheri-
cal in shape with particle sizes around 6 nm (Figure 6B).
Physical compatibility study with sodium 
chloride injection, glucose injection,  
and sterile water
All of the tested infusion solutions were physically com-
patible with the NIM-EPC-SGC-MMs during the 10-hour 
observation period at room temperature, with no NIM crys-
tals separating out from the mixed solutions at any degree 
of dilution. In contrast, crystals appeared only half an hour 
after the ten-times dilution of commercial NIM injections 
and immediately after 100- or 500-times dilution.
Table 2 Solubility of NIM-EPC-SGC-MMs
Sample Solubility  
(mg/mL)a
Solubilizing  
efficiencya
Drug loadinga
NIM-EPC-SGC-MMs 0.468 ± 0.009 93.8% ± 2.2% 1.17% ± 0.02%
Notes: aReported as means ± standard deviation; n = 3.
Abbreviation:  NIM-EPC-SGC-MMs,  nimodipine-egg  phosphatidylcholine-sodium 
glycocholate-mixed micelles.
In vivo studies in rats
The mean plasma concentration–time curves of NIM after 
intravenous administration of NIM injection and NIM-EPC-
SGC-MMs to rats (equivalent to 2 mg/kg of NIM; n = 5), are 
shown in Figure 7. The results indicate that the NIM-EPC-
SGC-MMs and NIM injection share the same trend. For both 
preparations, in the first 45 minutes, the elimination of NIM 
from the blood was rapid then became very slow after that. 
The concentration of NIM was at the minimum of 300 minutes 
and then could no longer be detected. Table 3 shows the main 
pharmacokinetic parameters in rats after intravenous injection 
of NIM injection and NIM-EPC-SGC-MMs (calculated with 
DAS 2.0 software). The area under the concentration–time 
curve from time zero to infinity, maximum concentration 
following administration, mean retention time, and half-life 
of NIM between the NIM-EPC-SGC-MM group and NIM 
injection group showed no significant differences (P . 0.05), 
indicating that the two formulations were bioequivalent.
Vascular irritability study in rabbits
The rabbit-ear vein irritation test was processed to evaluate 
the irritation of NIM-EPC-SGC-MMs and sodium chloride 
injection versus NIM injection. Compared with the NIM 
injection, the NIM-EPC-SGC-MM formulation-treated 
rabbit group did not show deep respiration. In addition, 
during infusion of the NIM injection, the rabbits struggled 
more   frequently than those in the NIM-EPC-SGC-MMs and 
sodium chloride injection group. After 5-days of   infusion, 
the ear vein of the rabbits in the NIM injection group showed 
vascular congestion and vascular lines were unclear. In this 
group, edema appeared at the surrounding tissue. In contrast, 
the ear vein of rabbits injected with NIM-EPC-SGC-MMs 
and sodium chloride injection only had slight phlebectasia, 
which disappeared 30 minutes after injection.
We viewed these results in histopathological slices, as 
shown in Figure 8. The histopathological damage caused 
by the NIM injection was observed microscopically as 
vasodilation, hemorrhage and degeneration around the vein 
wall, degeneration of the vein wall, edema around the vein, 
inflammatory cell infiltration around the vein, and endothelial 
cell swelling (Figure 8A). However, the results for NIM-
EPC-SGC-MMs and sodium chloride injection (Figure 8B 
and 8C) show no histopathological damage.
Discussion
It has been demonstrated that the PC-BS-MM system has 
great potential to improve the solubility of poorly water-
soluble drugs as a novel delivery vehicle, especially in 
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Figure 6 (A) Size and size distribution of the optimal NIM-EPC-SGC-MMs; (B) transmission electron micrograph of NIM-EPC-SGC-MMs (scale bar = 50 nm).
Abbreviation: NIM-EPC-SGC-MMs, nimodipine-egg phosphatidylcholine-sodium glycocholate-mixed micelles.
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Figure 7 Mean plasma concentration–time curves of NIM after intravenous injection of NIM injection and NIM-EPC-SGC-MMs in rats (n = 5). 
Note: Each point represents mean ± standard deviation.
Abbreviations: NIM, nimodipine; NIM-EPC-SGC-MMs, nimodipine-egg phosphatidylcholine-sodium glycocholate-mixed micelles.
solubilization of some lipophilic drugs. Among different 
BS, SGC has the highest capacity to solubilize soybean 
lecithin (SPC), and EPC was solubilized to a higher 
extent than SPC.15 The solubility of NIM in water was 
0.468 ± 0.009 mg/mL after the formation of optimized 
NIM-EPC-SGC-MMs. The solubility of NIM in EPC-
SGC-MMs was significantly improved, about 120-fold 
higher than that of free NIM with a water solubility of 
3.86 µg/mL,10 which suggests that the NIM-EPC-SGC-MM 
system is a promising strategy for improving the solubility 
of NIM in water.
To optimize the NIM-EPC-SGC-MM preparation, the 
four main parameters that may affect the solubilization 
potential of the system were studied: (1) EPC/SGC mass 
concentration ratio, (2) the total concentration of EPC and 
SGC, (3) the dose of NIM, and (4) the pH value.
First, the EPC/SGC mass concentration ratio was   evaluated 
and the solubilizing efficiency was employed as the evalua-
tion parameter. The highest solubilizing efficiency of NIM 
was obtained when the EPC/SGC mass   concentration ratio 
was 1:1. The EPC/SGC mass concentration ratio (1:1) was 
equal to the EPC mol fraction of 0.6, and EPC at a   maximum 
mol fraction of 0.6 could be incorporated in SGC to form 
a clear mixed-micellar solution.15 A further decrease in the 
amount of EPC (EPC/SGC mass   concentration ratio from 
1:1 to 0:1) did not improve but, remarkably, reduced NIM 
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Figure 8 Pathological paraffin sections (hematoxylin-eosin stain) from the ears of 
rabbits (×100 magnification). (A) Ear sample from rabbit given the NIM injection, 
showing vasodilation, hemorrhage, and degeneration around and of the vein wall 
as well as edema around the vein, inflammatory cell infiltration around the vein, 
and endothelial cell swelling. (B) Ear sample from rabbit given NIM-EPC-SGC-MMs. 
(C)  Ear  sample  from  rabbit  given  sodium  chloride  injection.  The  phenomenon 
shown in (A) was not observed in (B) or (C).
Abbreviations:  NIM,  nimodipine;  NIM-EPC-SGC-MMs,  nimodipine-egg 
phosphatidylcholine-sodium glycocholate-mixed micelles.
Table 3   The  main  pharmacokinetic  parameters  of  the  NIM 
injection and NIM-EPC-SGC-MMs in rats
Parameter NIM-EPC-SGC-MMs NIM injection
AUC(0–t) (µg ⋅ mL–1 ⋅ min) 434.851 ± 30.886 392.903 ± 34.172
AUC(0–∞) (µg ⋅ mL–1 ⋅ min) 461.911 ± 26.984 427.848 ± 23.123
MRT(0–t) (min) 62.722 ± 5.064 61.999 ± 9.887
MRT(0–∞) (min) 83.996 ± 9.373 95.386 ± 37.737
Cmax (µg/mL) 10.214 ± 1.136 9.144 ± 0.797
T1/2z (min) 84.312 ± 6.655 102.394 ± 46.483
CLz (mL ⋅ min–1 ⋅ g) 0.004 0.005
Notes: Data reported as means ± standard deviation; n = 5.
Abbreviations: AUC, area under the curve; MRT, mean retention time; NIM-EPC-
SGC-MMs, nimodipine-egg phosphatidylcholine-sodium glycocholate-mixed micelles.
solubilizing efficiency, indicating that the addition of EPC 
greatly enhanced the capacity of EPC-SGC-MMs to solu-
bilize NIM. This could be correlated with the ability of the 
formed MMs to reduce surface tension.17 In addition, when 
the ratio changed from 1:0.7 to 1:1, a significant increase in 
NIM solubilizing efficiency was observed. It was reported 
that an increase in the EPC concentration resulted in a higher 
viscosity and less partition of the drug into the mixed-micellar 
space.19
Regarding the effect of the total concentration of SGC 
and EPC on the solubility of NIM, the results showed that the 
optimum total concentration for the NIM-EPC-SGC-MMs 
was 40 mg/mL. According to the theory of micelle forma-
tion, PC-BS-MM formation is associated with the CMC, 
spontaneous curvature, and chemical structure of different 
BS and EPC.15,34 With an increase in the total concentration 
of SGC and EPC, the amount of single micelles increased 
and resulted in an improvement of the solubility of NIM. 
However, when the NIM within the formulation was all 
solubilized, the solubilizing efficiency did not improve 
further when more SGC and EPC were added. In addition, 
the relatively high solubilizing efficiency achieved by a 
lower total concentration of SGC and EPC could avoid the 
administration of redundant excipients.
The formation of drug-loaded micelles is significantly 
related to the properties of the drug, such as polarity; 
polarization degree; chain length; chain branching; and 
molecular size, shape, and structure.15,35 As shown by 
systematic research,15,36 the structure of PC-BS-MMs is 
widely accepted as a “mixed disk model.”37 In this model, 
the MM consists of a disk-like core in which BS and 
phospholipids interact, and BS surround its perimeter.35 
Drugs are generally inserted into the micelle hydrophobic 
core or peripheral hydrophilic micellar palisade layer. 
Like benzodiazepines,15 the planar aromatic ring of NIM 
contributes to the insertion of drug molecules into the 
lipophilic core of micelles. This corresponds to our results 
showing that NIM solubility improved when the lipophilic 
component increased with a greater proportion of EPC. 
The limiting concentration of NIM was 0.5 mg/mL in this 
optimized EPC-SGC-MM system. When the concentration 
of NIM was more than 0.5 mg/mL, the excess NIM would 
be temporarily stable in the hydrophilic micellar palisade 
layer; however, it would gradually separate out from the 
MM system, as a result of the many oxygen and nitrogen 
atoms in the NIM molecule, which can easily form hydro-
gen bonds with water.
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Under ionization conditions, BS have a strong solubilization 
effect.15–18 The pH value of glycocholic acid is 4.4.15 When 
the pH was below 4.4, glycocholic acid would precipitate. 
Thus, when the pH value increased from 2 to 6, resulting in an 
increased amount of ionized SGC, the solubilizing efficiency 
of NIM in the EPC-SGC-MMs was significantly enhanced. 
Therefore, considering the solubilizing efficiency, the stability 
of phospholipids,32 and physiological relevance, the pH value 
was adjusted to 7.4; this moderate pH value scale was applied 
to the preparation of the NIM-EPC-SGC-MMs.
We later analyzed some characteristics of the optimized 
formulation of the NIM-EPC-SGC-MMs, such as particle 
size, morphology, solubility, solubilizing efficiency, and 
drug loading. The narrow peak of size distribution and the 
morphological spherical shape indicated that the NIM-EPC-
SGC-MMs were relatively uniform and monodisperse.
The pyrene 1:3 ratio method has been reported as one of 
the most popular methods for measuring the CMC values of 
both pure micelle solutions and MMs.29,33,38,39 Pyrene mono-
mer emission spectra are related to vibronic fine structures, 
whose intensities are heavily dependent on the polarity of 
the microenvironment. As a hydrophobic molecule with 
low aqueous solubility (∼0.3 µM), pyrene was sensitive to   
a more hydrophobic environment.38 While the pyrene was 
solubilized in micelles, which resulted in the formation of 
hydrophobic domains, a significant decrease of I1/I3 ratio 
was observed.39 The I1/I3 ratio became finally steady with 
high surfactant concentration, proving that the pyrene was 
in a totally hydrophobic environment.
A physical compatibility study with sodium chloride 
injection, glucose injection, and sterile water was performed 
to evaluate the safety of the NIM-EPC-SGC-MMs for clinical 
use. When the NIM injection is diluted, NIM crystals usually 
appear, owing to the decrease of the organic solvent propor-
tion, which is dangerous for patients. Using EPC-SGC-MMs, 
NIM could be loaded into the micelle hydrophobic core. 
During dilution of NIM-EPC-SGC-MMs, the stability of the 
NIM-EPC-SGC-MMs was associated with the CMC. The 
entrapped NIM would not separate out from the MM system 
even when it was diluted 500-fold with the three injection 
solutions tested and the final total concentration of EPC and 
SGC was 0.8 mg/mL, suggesting that the concentration of 
the EPC-SGC-MMs was above the CMC in a wide dilution 
range. This showed that NIM-EPC-SGC-MMs were physi-
cally compatible with these injection solutions.
Pharmacokinetic study in vivo was also performed to fur-
ther understand the characteristics of NIM-EPC-SGC-MMs. 
No significant difference was found in the main pharma-
cokinetic parameters between NIM injection and NIM-EPC-
SGC-MMs. This may be due to the quick release of NIM from 
the MM system when administered by intravenous injection 
into the blood. To the best of our knowledge, the NIM-EPC-
SGC-MM system was in dynamic equilibrium. Moreover, 
the plasma protein-binding rate of NIM was 97%–99%. Such 
a high affinity of NIM to plasma protein could extract NIM 
from NIM-EPC-SGC-MMs. As free NIM in the NIM injec-
tion was also bound with plasma protein, the two formula-
tions share almost the same pharmaceutical profile.
A vascular irritability study in rabbits was performed to 
evaluate the safety of the formulations. The NIM injection 
caused a very serious vascular irritability in the ear vein of 
rabbits, which is in accordance with the results of clinical 
application.12 In contrast, NIM-EPC-SGC-MMs and sodium 
chloride injection caused almost no vascular irritability. The 
most reasonable explanation for the irritability of the NIM 
injection is the effect of the ethanol.11 Moreover, NIM could 
expand the blood vessel, resulting in increased vascular 
permeability.40 Increased vascular permeability would lead 
to the leakage of plasma, drugs, and ethanol. For treatment 
of subarachnoid hemorrhage, patients are given a long-term 
dosage regimen of about 10 hours duration for a continuous 
10 to 14 days.41 Clearly, the high percentage of ethanol would 
cause great pain, leading to noncompliance.11 Consequently, 
ethanol and leak damage could be the main causes of the vas-
cular irritation. NIM-EPC-SGC-MMs and sodium chloride 
injection would not have the undesired side effects associated 
with the mixed solvent.
Conclusion
In this study, NIM-EPC-SGC-MMs were prepared using the 
coprecipitation method. After optimization of the novel for-
mulation, NIM-EPC-SGC-MMs exhibited suitable particle 
size and high NIM water solubility. NIM-EPC-SGC-MMs 
were also physically compatible with sodium chloride injec-
tion, glucose injection, and sterile water at room temperature 
for up to 10 hours. Furthermore, the NIM-EPC-SGC-MMs 
and NIM injection exhibited almost the same pharmacoki-
netics. There was nearly no vascular irritation caused by the 
NIM-EPC-SGC-MMs, solving the main problem of NIM 
intravenous clinical application. As a result, the NIM-EPC-
SGC-MM system has been proven an attractive method for 
the intravenous administration of NIM.
Thus, with remarkable improvement in the water solubil-
ity of NIM and injection safety, NIM-EPC-SGC-MMs may 
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be a promising replacement for the NIM injection, which 
contains the organic solvent ethanol. In addition, NIM-EPC-
SGC-MMs can be prepared by a simple and convenient 
technology, therefore have the potential to be industrially 
produced on a large-scale.
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